{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(5)"],"submitter":["Huang CF"],"funding":["Kaohsiung Medical University","Kaohsiung Medical University Chung-Ho Memorial Hospital"],"pubmed_abstract":["<h4>Background/aims</h4>Direct-acting antivirals (DAAs) are highly effective in treating hepatitis C virus (HCV) infection. The long-term hepatic and extrahepatic outcomes of DAAs in chronic hepatitis C (CHC) patients receiving curative antivirals are elusive.<h4>Methods</h4>CHC patients were retrieved from two phase III sofosbuvir-based clinical trials conducted from 2013-2014. Patients who achieved a sustained virological response have been followed prospectively for 5 years since 2016. A propensity score-matched interferon-based historical control with a 1:3 ratio was used for comparison. Quality of life (QoL) was measured by the SF-36, liver fibrosis was measured by electrography, and fibrosis-related markers were followed annually in the prospective cohort.<h4>Results</h4>A total of 1"],"journal":["Infectious diseases and therapy"],"pagination":["1089-1101"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12084436"],"repository":["biostudies-literature"],"pubmed_title":["Long-Term Hepatic and Extrahepatic Outcomes of Chronic Hepatitis C Patients After Sofosbuvir-Based Treatment (LONGHEAD Study)."],"pmcid":["PMC12084436"],"pubmed_authors":["Kao JH","Byun KS","Yoon SK","Paik SW","Peng CY","Huang CF","Chen JJ","Sheen IS","Youn-Jae Lee","Kim YJ","Yu ML","Ahn SH","Tak WY","Yim HJ","Yeh ML","Kim YS","Lim YS","Tsai PC","Hsu YC","Chien RN","Baek YH","Hu TH","Wang HY","Chang TT","Chuang WL","Heo J","Kim JH","Dai CY","Jeong SH","Huang JF"],"additional_accession":[]},"is_claimable":false,"name":"Long-Term Hepatic and Extrahepatic Outcomes of Chronic Hepatitis C Patients After Sofosbuvir-Based Treatment (LONGHEAD Study).","description":"<h4>Background/aims</h4>Direct-acting antivirals (DAAs) are highly effective in treating hepatitis C virus (HCV) infection. The long-term hepatic and extrahepatic outcomes of DAAs in chronic hepatitis C (CHC) patients receiving curative antivirals are elusive.<h4>Methods</h4>CHC patients were retrieved from two phase III sofosbuvir-based clinical trials conducted from 2013-2014. Patients who achieved a sustained virological response have been followed prospectively for 5 years since 2016. A propensity score-matched interferon-based historical control with a 1:3 ratio was used for comparison. Quality of life (QoL) was measured by the SF-36, liver fibrosis was measured by electrography, and fibrosis-related markers were followed annually in the prospective cohort.<h4>Results</h4>A total of 1","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 May","modification":"2026-05-29T17:02:48.948Z","creation":"2026-04-08T05:25:51.598Z"},"accession":"S-EPMC12084436","cross_references":{"pubmed":["40205145"],"doi":["10.1007/s40121-025-01145-y"]}}